公开(公告)号：US11725052B2

公开(公告)日：2023-08-15

申请号：US17405275

申请日：2021-08-18

Applicant: Cephalon LLC

Inventor： Anna Mikaela Bracken ,  Adam Clarke ,  Bridget A. Cooksey ,  Anthony Gerard Doyle ,  Mark Terence Liddament ,  Matthew Pollard ,  Lynn Poulton ,  Anna Maria Matilda Quigley ,  Julia Rozenfeld ,  Marta Szabat

IPC: A61K39/00 ,  A61K39/395 ,  G01N33/53 ,  C12P21/06 ,  C12N5/02 ,  C12N15/00 ,  C07K16/00 ,  C07K16/46 ,  C07H21/04 ,  C07K16/28 ,  A61P17/10 ,  A61P29/00 ,  A61P35/04

CPC classification number: C07K16/28 ,  A61P17/10 ,  A61P29/00 ,  A61P35/04 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).